Akava Therapeutics is a small molecule therapeutics that inhibits protein aggregation, enzymes, and cancer for neurodegenerative diseases.
Akava Therapeutics has raised $7.3M in total funding. The most recent round was Grant. The last funding was announced in December 2024.
Akava Therapeutics's investors include National Institute on Aging.
Akava Therapeutics is headquartered in Winnetka, United States.
Akava Therapeutics is a small molecule therapeutics that inhibits protein aggregation, enzymes, and cancer for neurodegenerative diseases.
Akava Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Akava Therapeutics — Funding & Investors." VCBacked, December 17, 2024, https://www.vcbacked.co/company/akava-therapeutics. Accessed August 16, 2026.
VCBacked. (2024). Akava Therapeutics — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/akava-therapeutics
{{cite web |title=Akava Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/akava-therapeutics |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated